|
60 Companies |
|
66 Products |
|
66 Products |
|
78 Mechanisms of Action |
|
2 Trials |
|
573 News |
|
| «123456789101112» |
- Trial completion: Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 8, 2014
P1, N=7, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed
- donepezil / Generic mfg.
Trial completion: Randomized Controlled Study of Donepezil in Fragile X Syndrome (clinicaltrials.gov) - Apr 6, 2014
P2, N=45, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Completed
- lenalidomide / Generic mfg.
Trial termination: LENA-LMA-5t: LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 3, 2014
P4, N=4, Terminated, Sponsor: PETHEMA Foundation
Recruiting --> Completed Recruiting --> Terminated
- lenalidomide / Generic mfg.
Enrollment change: LENA-LMA-5t: LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 3, 2014
P4, N=4, Terminated, Sponsor: PETHEMA Foundation
Recruiting --> Terminated N=30 --> 4
- oxytocin / Generic mfg.
Trial initiation date: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - Apr 2, 2014
P1, N=24, Not yet recruiting, Sponsor: University of Florida
N=30 --> 4 Initiation date: Feb 2014 --> Jun 2014
- sodium valproate / Generic mfg.
Enrollment closed: RUBIVAL: Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial (clinicaltrials.gov) - Mar 31, 2014
P2, N=60, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Initiation date: Feb 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- ||| Trial completion: IVF008: Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD) (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=56, Completed, Sponsor: Natera, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Zomacton (somatropin) / Ferring
Trial initiation date, Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Jun 2014
- ||||| donepezil / Generic mfg.
New P2 trial: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living. (clinicaltrials.gov) - Mar 19, 2014
P2, N=60, Recruiting, Sponsor: Eisai Co., Ltd.
- Enrollment open: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=100, Recruiting, Sponsor: BEGUM AYDOGAN
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- Trial initiation date: Fat Distribution and Glucose Metabolism in Williams Syndrome (clinicaltrials.gov) - Mar 4, 2014
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Initiation date: Jun 2013 --> Dec 2013
- Enrollment open: Fat Distribution and Glucose Metabolism in Williams Syndrome (clinicaltrials.gov) - Mar 4, 2014
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Jun 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- |||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion: Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=150, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion: Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib (clinicaltrials.gov) - Feb 22, 2014
P2, N=387, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion: Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=96, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Trial completion: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=254, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- || somatropin / Generic mfg.
Enrollment closed: GeNeSIS: Observational Study of Somatropin Treatment in Children (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=23500, Active, not recruiting, Sponsor: Eli Lilly and Company
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||| Zorbtive (somatropin) / EMD Serono
Biomarker, Trial completion: PREDICT LT FUP: Long Term Follow up Study of Predictive Markers in GHD and TS Children (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=182, Completed, Sponsor: Merck KGaA
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment closed: CML 0206: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 5, 2014
P2, N=69, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- minocycline / Generic mfg.
New P2 trial: A-MANECE: Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome (clinicaltrials.gov) - Feb 4, 2014
P2, N=32, Recruiting, Sponsor: Puerta de Hierro University Hospital
- |||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Enrollment open: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 3, 2014
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome (clinicaltrials.gov) - Feb 3, 2014
P=N/A, N=35, Active, not recruiting, Sponsor: State University of New York - Upstate Medical University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Trial completion: A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=90, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Enrollment open: Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 26, 2014
P2, N=38, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial initiation date: Intensive Dysarthria Sessions in Adults and Children With Down Syndrome (clinicaltrials.gov) - Jan 23, 2014
P=N/A, N=12, Not yet recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Initiation date: Aug 2013 --> Jan 2014
- | basimglurant (NOE-101) / Noema Pharma
Enrollment closed: A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome (clinicaltrials.gov) - Jan 19, 2014
P2, N=47, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Aug 2013 --> Jan 2014 Recruiting --> Active, not recruiting
- ||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial initiation date: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Jan 18, 2014
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
Recruiting --> Active, not recruiting Initiation date: Oct 2013 --> Jan 2014
- || Enrollment closed: Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=3000, Active, not recruiting, Sponsor: Sequenom, Inc.
Initiation date: Oct 2013 --> Jan 2014 Recruiting --> Active, not recruiting
- rivastigmine / Generic mfg.
Enrollment closed: DS-Riv: Rivastigmine Study in Adolescents With Down Syndrome (clinicaltrials.gov) - Jan 15, 2014
P1/2, N=40, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion: MACS0911: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (clinicaltrials.gov) - Jan 15, 2014
P4, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed: Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=36, Active, not recruiting, Sponsor: Merlin G. Butler, MD, PhD
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| basimglurant (NOE-101) / Noema Pharma
Enrollment closed: A Study of RO4917523 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Jan 12, 2014
P2, N=185, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | diazoxide choline controlled release (DCCR) / Soleno Therap
New P1 trial: Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Jan 9, 2014
P1, N=12, Recruiting, Sponsor: Essentialis, Inc.
- erlotinib / Generic mfg.
Enrollment change: Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) (clinicaltrials.gov) - Jan 8, 2014
P1, N=6, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting N=16 --> 6
- erlotinib / Generic mfg.
Trial completion: Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) (clinicaltrials.gov) - Jan 8, 2014
P1, N=6, Completed, Sponsor: Mayo Clinic
N=16 --> 6 Recruiting --> Completed
- Enrollment change: SEQ21: Trisomy of Chromosome 21 Diagnosis by High Output Sequencing (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=976, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed N=255 --> 976
- Trial completion: SEQ21: Trisomy of Chromosome 21 Diagnosis by High Output Sequencing (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=976, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=255 --> 976 Recruiting --> Completed
- ||||| basmisanil (RG1662) / Roche
New P2 trial: A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS) (clinicaltrials.gov) - Dec 29, 2013
P2, N=180, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Zomacton (somatropin) / Ferring
Adherence: ZOMAXEPT: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=90, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- | Vivelle (estradiol transdermal system) / Sanofi, Hisamitsu, Novartis, Estreva oral (estradiol oral) / EMD Serono, Estrace (estradiol) / AbbVie
Trial completion: Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism (clinicaltrials.gov) - Dec 18, 2013
P4, N=41, Completed, Sponsor: Nemours Children's Clinic
Recruiting --> Completed Active, not recruiting --> Completed
- | beloranib (ZGN-440) / Larimar Therap
Trial completion: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome (clinicaltrials.gov) - Dec 16, 2013
P2, N=17, Completed, Sponsor: Zafgen, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- oxytocin / Generic mfg.
New P1 trial: Oxytocin Trial in Prader-Willi Syndrome (clinicaltrials.gov) - Dec 15, 2013
P1, N=24, Not yet recruiting, Sponsor: University of Florida
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion, Combination therapy: NICOLI: Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (clinicaltrials.gov) - Dec 11, 2013
P4, N=4, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Biomarker, Trial completion: EMR 200104_010: First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study (clinicaltrials.gov) - Nov 25, 2013
P4, N=458, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=3800, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | basmisanil (RG1662) / Roche
Trial completion: A Study of RG1662 in Individuals With Down Syndrome (clinicaltrials.gov) - Nov 12, 2013
P1, N=35, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial initiation date: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=5600, Recruiting, Sponsor: Centre Hospitalier Universitaire de Québec, CHU de Québec
Recruiting --> Completed Initiation date: Aug 2013 --> Nov 2013
- Enrollment open: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=5600, Recruiting, Sponsor: Centre Hospitalier Universitaire de Québec, CHU de Québec
Initiation date: Aug 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- basmisanil (RG1662) / Roche
Enrollment change: A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662 (clinicaltrials.gov) - Nov 4, 2013
P1, N=13, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=17 --> 13
- | basmisanil (RG1662) / Roche
Trial completion: A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662 (clinicaltrials.gov) - Nov 4, 2013
P1, N=13, Completed, Sponsor: Hoffmann-La Roche
N=17 --> 13 Recruiting --> Completed